Rafael Holdings (RFL) – Globe Newswire
-
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
-
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
-
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
-
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
-
Rafael Holdings Announces up to $5 Million Share Repurchase Program
-
Rafael Holdings Announces up to $5 Million Share Repurchase Program
-
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
-
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
-
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
-
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
-
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
-
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
-
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
-
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
-
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
-
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
-
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
-
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
-
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastroint
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
-
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
-
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
-
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO)
-
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
-
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
-
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results
-
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results
-
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022
-
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022
-
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Pat
-
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Pat
-
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patie
-
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patie
-
Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results
-
Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results
-
Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting an
-
Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting an
-
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus
-
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus
-
Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
-
Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
-
European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma
-
European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma
-
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed
-
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed
-
Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute M
-
Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute M
-
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
-
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
Back to RFL Stock Lookup